

Francesco Bertolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/315893/publications.pdf>

Version: 2024-02-01

246
papers

12,007
citations

25034

57
h-index

30922

102
g-index

256
all docs

256
docs citations

256
times ranked

12759
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). <i>Scientific Reports</i> , 2022, 12, 1341.	3.3	11
2	The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. <i>Scientific Reports</i> , 2022, 12, 3234.	3.3	14
3	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. <i>Cell Death Discovery</i> , 2022, 8, 106.	4.7	10
4	Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. <i>International Journal of Cancer</i> , 2022, 151, 1791-1803.	5.1	7
5	Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 685-697.	0.9	31
6	Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly(ADP-ribose) polymerase inhibitors: A single-center experience. <i>International Journal of Cancer</i> , 2021, 148, 170-177.	5.1	9
7	Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1359.	4.1	5
8	Archaeogenomic distinctiveness of the Isthmo-Colombian area. <i>Cell</i> , 2021, 184, 1706-1723.e24.	28.9	30
9	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. <i>Current Medicinal Chemistry</i> , 2021, 28, 2114-2136.	2.4	6
10	A "two-hit" (chemo)therapy to improve checkpoint inhibition in cancer. <i>Oncoscience</i> , 2021, 8, 55-57.	2.2	3
11	Abstract 1653: A single-cell atlas of the effect of chemotherapeutics over intratumoral immune cells reveals that combining an alkylating agent and a vinca alkaloid can activate antigen presenting cells and increase tcf1+ stem-like CD8+ T-cells, thus improving anti-PD-1 efficacy in triple negative breast cancer and lymphoma. , 2021, , ,		0
12	The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses. <i>Cancers</i> , 2021, 13, 5042.	3.7	7
13	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies. <i>Life</i> , 2021, 11, 1131.	2.4	3
14	SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial. <i>Blood</i> , 2021, 138, 3436-3436.	1.4	2
15	Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2744-2750.	3.8	39
16	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1225.	2.8	14
17	Plant TDP1 (Tyrosyl-DNA Phosphodiesterase 1): A Phylogenetic Perspective and Gene Expression Data Mining. <i>Genes</i> , 2020, 11, 1465.	2.4	2
18	Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven" venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2277-2279.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. <i>Blood</i> , 2020, 136, 766-768.	1.4	60
20	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	3.5	12
21	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. <i>European Journal of Cancer</i> , 2019, 122, 22-41.	2.8	7
22	Identifying Drug Repurposing Opportunities in Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 82-87.	2.0	8
23	Desperately seeking Models to find the right partner and the best use for checkpoint inhibitors. <i>British Journal of Cancer</i> , 2019, 120, 139-140.	6.4	2
24	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019, 104, 729-737.	3.5	58
25	Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features. <i>Blood</i> , 2019, 134, 5414-5414.	1.4	0
26	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. <i>British Journal of Cancer</i> , 2018, 118, 1329-1336.	6.4	75
27	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	3.5	48
28	The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. <i>Leukemia</i> , 2018, 32, 911-919.	7.2	34
29	Stromal Cell-Derived Factor-1 Promotes Endothelial Colony-Forming Cell Migration Through the Ca ²⁺ -Dependent Activation of the Extracellular Signal-Regulated Kinase 1/2 and Phosphoinositide 3-Kinase/AKT Pathways. <i>Stem Cells and Development</i> , 2018, 27, 23-34.	2.1	41
30	Mitochondrial Complex I activity signals antioxidant response through ERK5. <i>Scientific Reports</i> , 2018, 8, 7420.	3.3	38
31	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. <i>Theranostics</i> , 2018, 8, 3856-3869.	10.0	48
32	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. <i>Oncotarget</i> , 2018, 9, 1114-1129.	1.8	22
33	A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease. <i>Blood</i> , 2018, 132, 2189-2189.	1.4	0
34	Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. <i>Cell Reports</i> , 2017, 19, 774-784.	6.4	82
35	Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1292-1296.	1.4	70
36	P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting. <i>Journal of Thoracic Oncology</i> , 2017, 12, S812.	1.1	1

#	ARTICLE	IF	CITATIONS
37	The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway. <i>Scientific Reports</i> , 2017, 7, 10654.	3.3	23
38	Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5169-5182.	0.9	60
39	GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer. <i>Oncoscience</i> , 2017, 4, 126-127.	2.2	8
40	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <i>Oncotarget</i> , 2017, 8, 5895-5908.	1.8	45
41	Roles of obesity in the development and progression of breast cancer. <i>Discovery Medicine</i> , 2017, 24, 183-190.	0.5	5
42	Next generation metronomic chemotherapyâ€™ report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€™8 May 2016, Mumbai. <i>Ecanermedalscience</i> , 2016, 10, 689.	1.1	10
43	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2146-2154.	7.0	26
44	A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition. <i>EBioMedicine</i> , 2016, 10, 13-14.	6.1	4
45	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. <i>Scientific Reports</i> , 2016, 6, 18673.	3.3	46
46	Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. <i>EBioMedicine</i> , 2016, 3, 43-53.	6.1	41
47	Characterization of Cancer Stem Cells. <i>Methods in Molecular Biology</i> , 2016, 1464, 49-62.	0.9	13
48	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	3.3	28
49	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma â€™ a case report. <i>Scientific Reports</i> , 2015, 5, 14829.	3.3	2
50	Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with krasv12 Cells. <i>Scientific Reports</i> , 2015, 5, 13047.	3.3	1
51	Lessons from the first ecaner symposium on angiogenesis in gastric cancer. <i>Ecanermedalscience</i> , 2015, 9, 553.	1.1	0
52	Biomarkers of cancer angioprevention for clinical studies. <i>Ecanermedalscience</i> , 2015, 9, 600.	1.1	6
53	Stem cells from adipose tissue and breast cancer: hype, risks and hope. <i>British Journal of Cancer</i> , 2015, 112, 419-423.	6.4	81
54	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 889-898.	4.1	30

#	ARTICLE	IF	CITATIONS
55	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015, 24, 263-271.	2.2	13
56	Safety of Lipofilling in Patients with Breast Cancer. <i>Clinics in Plastic Surgery</i> , 2015, 42, 339-344.	1.5	40
57	Drug repurposing in oncology—patient and health systems opportunities. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 732-742.	27.6	247
58	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. <i>International Journal of Cancer</i> , 2015, 136, E534-44.	5.1	119
59	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. <i>Oncotarget</i> , 2015, 6, 19228-19245.	1.8	28
60	P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3684-3684.	1.4	0
61	Mechanisms of obesity in the development of breast cancer. <i>Discovery Medicine</i> , 2015, 20, 121-8.	0.5	14
62	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	1.1	26
63	Paradoxical effects of metformin on endothelial cells and angiogenesis. <i>Carcinogenesis</i> , 2014, 35, 1055-1066.	2.8	118
64	About CD45 ⁺ /CD31 ⁺ /CD105 ⁺ Circulating Cells in Patients with Gynecologic Malignancies—Letter. <i>Clinical Cancer Research</i> , 2014, 20, 1393-1393.	7.0	0
65	Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 545-550.	2.4	15
66	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
67	A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e114713.	2.5	17
68	Adipose tissue and breast cancer progression: A link between metabolism and cancer. <i>Breast</i> , 2013, 22, S48-S49.	2.2	20
69	Contribution of endothelial precursors of adipose tissue to breast cancer: Progression-link with fat graft for reconstructive surgery. <i>Annales D'Endocrinologie</i> , 2013, 74, 106-107.	1.4	10
70	Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. <i>Drug Discovery Today</i> , 2013, 18, 193-201.	6.4	57
71	Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. <i>Annals of Oncology</i> , 2013, 24, 1479-1484.	1.2	172
72	Complementary Populations of Human Adipose CD34 ⁺ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5880-5891.	0.9	91

#	ARTICLE	IF	CITATIONS
73	On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. <i>British Journal of Cancer</i> , 2013, 108, 1387-1387.	6.4	4
74	Definition of miRNAs Expression Profile in Glioblastoma Samples: The Relevance of Non-Neoplastic Brain Reference. <i>PLoS ONE</i> , 2013, 8, e55314.	2.5	22
75	Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2013, 8, e74345.	2.5	28
76	Trafficking of Cells from Adipose Tissue to Tumor Microenvironment. , 2013, , 147-163.		0
77	Lenalidomide for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 367, 573-575.	27.0	4
78	Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. <i>Laboratory Investigation</i> , 2012, 92, 952-966.	3.7	65
79	Locoregional recurrence risk after lipofilling in breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 582-588.	1.2	203
80	Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	13
81	Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential. <i>Neoplasia</i> , 2012, 14, 1057-IN14.	5.3	24
82	The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression. <i>Cancer Research</i> , 2012, 72, 325-334.	0.9	138
83	miRNAs Expression Analysis in Paired Fresh/Frozen and Dissected Formalin Fixed and Paraffin Embedded Glioblastoma Using Real-Time PCR. <i>PLoS ONE</i> , 2012, 7, e35596.	2.5	34
84	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. <i>Clinical Breast Cancer</i> , 2012, 12, 207-214.	2.4	59
85	Adipose tissue cells, lipotransfer and cancer: A challenge for scientists, oncologists and surgeons. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 209-214.	7.4	45
86	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. <i>Breast</i> , 2012, 21, 309-313.	2.2	25
87	Circulating Endothelial Cells and Circulating Endothelial Progenitors. <i>Recent Results in Cancer Research</i> , 2012, 195, 163-170.	1.8	14
88	Plasma levels of IL-8 and g-CSF in high-grade gliomas treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2083-2083.	1.6	5
89	Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium. <i>PLoS ONE</i> , 2012, 7, e51109.	2.5	23
90	Evaluation of Circulating Endothelial Precursor Cells in Cancer Patients. <i>Methods in Molecular Biology</i> , 2012, 904, 165-172.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Circulating endothelial cells as biomarkers for patients receiving bevacizumab. <i>Lancet Oncology</i> , The, 2011, 12, 217-218.	10.7	4
92	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 718-725.	4.4	50
93	In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. <i>Leukemia</i> , 2011, 25, 733-736.	7.2	23
94	Response to anti-angiogenesis: An ever changing feature. <i>Breast</i> , 2011, 20, S61-S62.	2.2	2
95	Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. <i>Drug Discovery Today</i> , 2011, 16, 1052-1060.	6.4	35
96	Circulating perivascular progenitors: A target of PDGFR inhibition. <i>International Journal of Cancer</i> , 2011, 129, 1344-1350.	5.1	21
97	Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Clinical Cancer Research</i> , 2011, 17, 6163-6173.	7.0	33
98	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. <i>Cancer Research</i> , 2011, 71, 1362-1373.	0.9	117
99	Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice. <i>Cancer Research</i> , 2011, 71, 6986-6996.	0.9	102
100	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	2.1	61
101	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e21369.	2.5	56
102	Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel. <i>International Journal of Developmental Biology</i> , 2011, 55, 395-398.	0.6	4
103	CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases. <i>Blood</i> , 2011, 118, 2208-2208.	1.4	0
104	Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd. <i>Blood</i> , 2011, 118, 4700-4700.	1.4	0
105	Simultaneous characterization of progenitor cell compartments in adult human liver. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 31-40.	1.5	8
106	Sex-related efficiency in NSG mouse engraftment. <i>Blood</i> , 2010, 116, 2616-2617.	1.4	16
107	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. <i>BMC Cancer</i> , 2010, 10, 644.	2.6	20
108	Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 131-137.	7.4	12

#	ARTICLE	IF	CITATIONS
109	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. <i>Leukemia Research</i> , 2010, 34, 454-457.	0.8	12
110	Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. <i>Cancers</i> , 2010, 2, 1027-1039.	3.7	1
111	Miniaturized FISH for screening of onco-hematological malignancies. <i>BioTechniques</i> , 2010, 49, 497-504.	1.8	39
112	Rituximab and Subcutaneous 2-Chloro-2'-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2233-2238.	1.6	56
113	Crystallin is a bcl-2 mRNA binding protein involved in overexpression in cell acute lymphocytic leukemia. <i>FASEB Journal</i> , 2010, 24, 1852-1865.	0.5	24
114	Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 682-685.	3.4	9
115	Circulating endothelial cells as biomarkers in clinical oncology. <i>Microvascular Research</i> , 2010, 79, 224-228.	2.5	50
116	EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors. <i>PLoS ONE</i> , 2010, 5, e12015.	2.5	23
117	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy. , 2010, , 257-273.		0
118	Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. <i>Frontiers in Bioscience - Scholar</i> , 2009, S1, 304-318.	2.1	13
119	Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. <i>Oncology</i> , 2009, 77, 358-365.	1.9	9
120	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. <i>Cancer Research</i> , 2009, 69, 7524-7528.	0.9	78
121	Quantification of Circulating Endothelial Cells by Flow Cytometry. <i>Clinical Cancer Research</i> , 2009, 15, 3640-3640.	7.0	1
122	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. <i>Clinical Cancer Research</i> , 2009, 15, 7652-7657.	7.0	102
123	The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 27-32.	7.4	22
124	Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. <i>Breast</i> , 2009, 18, S48-S50.	2.2	4
125	Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. <i>British Journal of Haematology</i> , 2009, 144, 803-805.	2.5	15
126	Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses. <i>Clinical Cancer Research</i> , 2009, 15, 267-273.	7.0	153

#	ARTICLE	IF	CITATIONS
127	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009, 20, 197-203.	1.4	18
128	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 ⁺ cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	1.4	62
129	Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 95-101.	5.9	15
130	Human acute leukemia cells injected in NOD/LtSz- <i>scid</i> /IL-2R ^β null mice generate a faster and more efficient disease compared to other NOD/ <i>scid</i> -related strains. <i>International Journal of Cancer</i> , 2008, 123, 2222-2227.	5.1	155
131	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	0.8	1
132	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. <i>British Journal of Cancer</i> , 2008, 99, 1564-1571.	6.4	43
133	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. <i>BJU International</i> , 2008, 101, 884-888.	2.5	23
134	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	16.8	424
135	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4899-4905.	1.6	280
136	Circulating Endothelial Cell Number and Viability Are Reduced by Exposure to High Altitude. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2008, 15, 53-58.	1.7	12
137	Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, E54; author reply E55.	7.1	51
138	The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification. <i>Current Pharmaceutical Design</i> , 2008, 14, 3780-3789.	1.9	8
139	Human acute leukemia cells injected in NOD/LtSz- <i>scid</i> /IL-2R ^β null mice generate a faster and more efficient disease compared to other NOD/ <i>scid</i> -related strains. , 2008, 123, 2222.		1
140	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. <i>Blood</i> , 2008, 112, 1885-1885.	1.4	0
141	Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34 ⁺ cell Population with Intrinsic Resistance to IMATINIB Treatment. <i>Blood</i> , 2008, 112, 4221-4221.	1.4	0
142	IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease. <i>Blood</i> , 2008, 112, 1169-1169.	1.4	0
143	Metronomic Antiangiogenic Chemotherapy: Questions and Answers. , 2008, , 593-607.		0
144	Surrogate Markers of Angiogenesis. , 2008, , 795-808.		0

#	ARTICLE	IF	CITATIONS
145	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. <i>Blood</i> , 2007, 109, 533-542.	1.4	93
146	Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. <i>Hepatology</i> , 2007, 45, 1218-1228.	7.3	12
147	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 133-139.	2.0	47
148	Molecular and cellular biomarkers for angiogenesis in clinical oncology. <i>Drug Discovery Today</i> , 2007, 12, 806-812.	6.4	84
149	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. <i>Blood</i> , 2007, 110, 5116-5116.	1.4	0
150	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006, 108, 452-459.	1.4	242
151	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. <i>Histopathology</i> , 2006, 48, 529-535.	2.9	14
152	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. <i>Nature Reviews Cancer</i> , 2006, 6, 835-845.	28.4	559
153	Peripheral T-lymphocyte subsets in patients treated with Rituximabâ€“Chlorambucil combination therapy for indolent NHL. <i>Annals of Hematology</i> , 2006, 85, 813-814.	1.8	8
154	On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent. <i>Journal of Clinical Oncology</i> , 2006, 24, 4040-4040.	1.6	18
155	High-Dose Celecoxib and Metronomic â€œLow-doseâ€“Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Nonâ€“Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5190-5198.	7.0	106
156	Comparison of Three Different NOD/SCID-Related Strains in Preclinical Models of Acute Leukemia.. <i>Blood</i> , 2006, 108, 2361-2361.	1.4	0
157	SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 318-322.	1.2	14
158	Targeting VE-cadherin (while naked, and not engaged). <i>Blood</i> , 2005, 105, 4157-4157.	1.4	0
159	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , 2005, 106, 3058-3061.	1.4	252
160	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis. <i>Cancer Cell</i> , 2005, 7, 101-111.	16.8	332
161	Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. <i>Breast</i> , 2005, 14, 466-479.	2.2	84
162	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-Î²) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	2.5	59

#	ARTICLE	IF	CITATIONS
163	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. <i>Journal of Pathology</i> , 2005, 206, 337-345.	4.5	39
164	Circulating endothelial cells. <i>Thrombosis and Haemostasis</i> , 2005, 93, 228-235.	3.4	337
165	Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. <i>Current Cancer Drug Targets</i> , 2005, 5, 551-559.	1.6	48
166	Circulating Endothelial Progenitor Cells. <i>New England Journal of Medicine</i> , 2005, 353, 2613-2616.	27.0	16
167	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1345-1351.	1.3	38
168	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. <i>Blood</i> , 2005, 106, 1730-1730.	1.4	0
169	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.9	83
170	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	5.5	20
171	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	2.2	20
172	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-q23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. <i>British Journal of Haematology</i> , 2004, 124, 289-298.	2.5	26
173	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	5.1	16
174	Skeletal muscle differentiation potential of human adult bone marrow cells. <i>Experimental Cell Research</i> , 2004, 295, 66-78.	2.6	54
175	Autologous Peripheral Blood Stem Cell Transplantation for Myocardial Regeneration: A Novel Strategy for Cell Collection and Surgical Injection. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1808-1812.	1.3	73
176	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6039-6046.	7.0	18
177	AGF will make you blush. <i>Blood</i> , 2004, 103, 3610-3611.	1.4	0
178	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. <i>Blood</i> , 2004, 104, 1662-1670.	1.4	111
179	Extracellular UTP Affects In Vitro Migration and In Vivo Homing and Engraftment of CD34+ Hematopoietic Stem Cells.. <i>Blood</i> , 2004, 104, 4122-4122.	1.4	3
180	Lymphoma Cell Detection and Follow-Up in the Rituximab Era: Concordance between Flow Cytometry, Qualitative/Quantitative PCR and FISH in the Marrow and Blood from 647 Patients.. <i>Blood</i> , 2004, 104, 1376-1376.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab.. <i>Blood</i> , 2004, 104, 4629-4629.	1.4	0
182	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003, 120, 695-698.	2.5	18
183	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 271-277.	2.5	30
184	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 ⁺ human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	2.5	12
185	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	5.5	22
186	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. <i>Human Pathology</i> , 2003, 34, 41-47.	2.0	19
187	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. <i>Leukemia and Lymphoma</i> , 2003, 44, 299-302.	1.3	7
188	Strategies to Investigate Circulating Endothelial Cells in Cancer. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 503-506.	0.3	13
189	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2003, 522, 83-97.	1.6	82
190	Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. <i>Clinical Cancer Research</i> , 2003, 9, 377-82.	7.0	99
191	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , 2003, 63, 4342-6.	0.9	375
192	Chimerism of the Transplanted Heart. <i>New England Journal of Medicine</i> , 2002, 346, 1410-1412.	27.0	23
193	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. <i>Journal of Clinical Oncology</i> , 2002, 20, 4169-4180.	1.6	361
194	Short- and long-term safety of the 2×10^6 CD34 ⁺ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. <i>Annals of Oncology</i> , 2002, 13, 983-984.	1.2	2
195	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. <i>Experimental Hematology</i> , 2002, 30, 905-914.	0.4	34
196	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	2.5	87
197	CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 3106-12.	0.9	166
198	Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. <i>Lancet Oncology</i> , The, 2001, 2, 595.	10.7	3

#	ARTICLE	IF	CITATIONS
199	Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. <i>Annals of Oncology</i> , 2001, 12, 987-990.	1.2	81
200	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. <i>Blood</i> , 2001, 97, 3658-3661.	1.4	401
201	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2001, 92, 666-670.	5.1	27
202	Title is missing!. <i>Annals of Oncology</i> , 2001, 12, 1333-1333.	1.2	0
203	Adverse effects associated with extracorporeal photochemotherapy. <i>Transfusion</i> , 2000, 40, 121-121.	1.6	17
204	REPLY TO GUNSILIUS ET AL. <i>British Journal of Haematology</i> , 2000, 108, 662-663.	2.5	0
205	Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000, 14, 1477-1482.	7.2	44
206	The thin red line. <i>Experimental Hematology</i> , 2000, 28, 993-1000.	0.4	77
207	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	1.4	84
208	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	1.4	8
209	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	2.5	151
210	Angiogenesis in myelodysplastic syndromes. <i>British Journal of Cancer</i> , 1999, 81, 1398-1401.	6.4	260
211	Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results. <i>Bone Marrow Transplantation</i> , 1998, 22, 693-698.	2.4	29
212	Effects of storage temperature and time on cord blood progenitor cells. <i>Transfusion</i> , 1998, 38, 615-617.	1.6	6
213	Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. <i>Annals of Oncology</i> , 1998, 9, 913-916.	1.2	8
214	Placental-Blood Transplantation. <i>New England Journal of Medicine</i> , 1997, 336, 68-70.	27.0	7
215	Megakaryocytic Progenitors Can Be Generated Ex Vivo and Safely Administered to Autologous Peripheral Blood Progenitor Cell Transplant Recipients. <i>Blood</i> , 1997, 89, 2679-2688.	1.4	177
216	Multilineage Long-Term Engraftment Potential of Drug-Resistant Hematopoietic Progenitors. <i>Blood</i> , 1997, 90, 3027-3036.	1.4	32

#	ARTICLE	IF	CITATIONS
217	A new "two step"™ procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 615-619.	2.4	19
218	Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. <i>Bone Marrow Transplantation</i> , 1997, 20, 167-169.	2.4	17
219	Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 1997, 75, 1368-1372.	6.4	23
220	A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. <i>Transfusion</i> , 1996, 36, 128-132.	1.6	100
221	Functional and Morphological Characterization of Immunomagnetically Selected CD34 ⁺ Hematopoietic Progenitor Cells. <i>Stem Cells</i> , 1996, 14, 430-438.	3.2	31
222	Gene Transfer-Mediated Generation of Drug-Resistant Hemopoiesis. <i>Leukemia and Lymphoma</i> , 1996, 21, 17-23.	1.3	3
223	The effect of interleukin-12 in ex-vivo expansion of human haemopoietic progenitors. <i>British Journal of Haematology</i> , 1995, 90, 935-938.	2.5	12
224	Comparative Study of Different Procedures for the Collection and Banking of Umbilical Cord Blood. <i>Stem Cells and Development</i> , 1995, 4, 29-36.	1.0	76
225	A multicenter evaluation of reproducibility of swirling in platelet concentrates. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. <i>Transfusion</i> , 1994, 34, 796-801.	1.6	71
226	Retrovirus-mediated transfer of the multidrug resistance gene into human haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1994, 88, 318-324.	2.5	39
227	STORAGE IN SYNTHETIC MEDIUM AND LEUKOÆDEPLETION OF PLATELET CONCENTRATES. <i>Vox Sanguinis</i> , 1994, 67, 155-158.	1.5	4
228	In Vitro Assessment of the Quality of Stored Platelet Concentrates. <i>Transfusion Medicine Reviews</i> , 1994, 8, 29-36.	2.0	176
229	Role of Lactate in Platelet Storage Lesion. <i>Vox Sanguinis</i> , 1993, 65, 194-198.	1.5	31
230	PLATELET QUALITY AND REDUCTION OF HLA EXPRESSION IN ACIDÆTREATED PLATELET CONCENTRATES. <i>British Journal of Haematology</i> , 1993, 83, 525-527.	2.5	10
231	White cell-reduced red cells prepared by filtration: a critical evaluation of current filters and methods for counting residual white cells. <i>Transfusion</i> , 1993, 33, 128-133.	1.6	52
232	Platelet concentrates from buffy coats: Improved conditions for preparation and evaluation in routine clinical use. <i>Transfusion Science</i> , 1993, 14, 41-46.	0.6	11
233	Umbilical Cord Blood Banking: Evaluation of the Collection Procedure and of CFU-GM Content. <i>Stem Cells and Development</i> , 1993, 2, 233-234.	1.0	7
234	Platelet Concentrates Stored in Synthetic Medium after Filtration. <i>Vox Sanguinis</i> , 1992, 62, 82-86.	1.5	20

#	ARTICLE	IF	CITATIONS
235	Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. <i>Transfusion</i> , 1992, 32, 9-16.	1.6	51
236	Role of acetate during platelet storage in a synthetic medium. <i>Transfusion</i> , 1992, 32, 152-156.	1.6	70
237	Platelet Concentrates Stored in Synthetic Medium after Filtration. <i>Vox Sanguinis</i> , 1992, 62, 82-86.	1.5	19
238	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb/IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. <i>Vox Sanguinis</i> , 1990, 59, 201-204.	1.5	16
239	Removal of white cells from red cells by transfusion through a new filter. <i>Transfusion</i> , 1990, 30, 30-33.	1.6	71
240	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb/IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. <i>Vox Sanguinis</i> , 1990, 59, 201-204.	1.5	30
241	Leukocyte-Poor Blood Components: A Purer and Safer Transfusion Product for Recipients?. <i>Transfusion Medicine Reviews</i> , 1990, 4, 19-23.	2.0	16
242	Platelet concentrates prepared from pooled buffy-coats and stored in a glucose-free crystalloid medium. The Milan experience. <i>Transfusion Science</i> , 1990, 11, 357-362.	0.6	12
243	Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. <i>Transfusion</i> , 1989, 29, 605-609.	1.6	101
244	The Risk of Acquiring Transfusion-Transmissible Infections. <i>Vox Sanguinis</i> , 1988, 55, 186-187.	1.5	1
245	Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. <i>Transfusion</i> , 1987, 27, 402-405.	1.6	70
246	Preparation of Leukocyte-Free Platelets for Transfusion by Filtration through Cotton Wool. <i>Vox Sanguinis</i> , 1983, 44, 115-120.	1.5	48